Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; 27 of the 41 sources its claims cite were checked for support.

Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome

Open access

Abstract

BACKGROUND: Familial chylomicronemia syndrome is a genetic disorder associated with severe hypertriglyceridemia and severe acute pancreatitis. Olezarsen reduces the plasma triglyceride level by reducing hepatic synthesis of apolipoprotein C-III. METHODS: In a phase 3, double-blind, placebo-controlled trial, we randomly assigned patients with genetically identified familial chylomicronemia syndrome to receive olezarsen at a dose of 80 mg or 50 mg or placebo subcutaneously every 4 weeks for 49 weeks. There were two primary end points: the difference between the 80-mg olezarsen group and the placebo group in the percent change in the fasting triglyceride level from baseline to 6 months, and (to be assessed if the first was significant) the difference between the 50-mg olezarsen group and the placebo group. Secondary end points included the mean percent change from baseline in the apolipoprotein C-III level and an independently adjudicated episode of acute pancreatitis. RESULTS: A total of 66 patients underwent randomization; 22 were assigned to the 80-mg olezarsen group, 21 to the 50-mg olezarsen group, and 23 to the placebo group. At baseline, the mean (±SD) triglyceride level among the patients was 2630±1315 mg per deciliter, and 71% had a history of acute pancreatitis within the previous 10 years. Triglyceride levels at 6 months were significantly reduced with the 80-mg dose of olezarsen as compared with placebo (-43.5 percentage points; 95% confidence interval [CI], -69.1 to -17.9; P<0.001) but not with the 50-mg dose (-22.4 percentage points; 95% CI, -47.2 to 2.5; P = 0.08). The difference in the mean percent change in the apolipoprotein C-III level from baseline to 6 months in the 80-mg group as compared with the placebo group was -73.7 percentage points (95% CI, -94.6 to -52.8) and between the 50-mg group as compared with the placebo group was -65.5 percentage points (95% CI, -82.6 to -48.3). By 53 weeks, 11 episodes of acute pancreatitis had occurred in the placebo group, and 1 episode had occurred in each olezarsen group (rate ratio [pooled olezarsen groups vs. placebo], 0.12; 95% CI, 0.02 to 0.66). Adverse events of moderate severity that were considered by a trial investigator at the site to be related to the trial drug or placebo occurred in 4 patients in the 80-mg olezarsen group. CONCLUSIONS: In patients with familial chylomicronemia syndrome, olezarsen may represent a new therapy to reduce plasma triglyceride levels. (Funded by Ionis Pharmaceuticals; Balance ClinicalTrials.gov number, NCT04568434.).

Overview

CoChat Summary

TL;DR

In a phase 3 trial of patients with genetically identified familial chylomicronemia syndrome, olezarsen 80 mg every 4 weeks significantly reduced fasting triglycerides at 6 months versus placebo, while the 50-mg dose did not. Olezarsen also reduced apolipoprotein C-III and was associated with fewer adjudicated acute pancreatitis episodes over 53 weeks.

Key findings

  • The 80-mg olezarsen group had a least-squares mean reduction in fasting triglycerides from baseline to 6 months of −43.5 percentage points versus placebo (95% CI, −69.1 to −17.9; P<0.001); the 50-mg dose did not meet significance (−22.4 percentage points; 95% CI, −47.2 to 2.5; P=0.08).
  • Apolipoprotein C-III reductions from baseline to 6 months were −73.7 percentage points for 80 mg vs placebo (95% CI, −94.6 to −52.8) and −65.5 percentage points for 50 mg vs placebo (95% CI, −82.6 to −48.3).
  • By 53 weeks, adjudicated acute pancreatitis occurred in 11 episodes in the placebo group and 1 episode in each olezarsen group (rate ratio for pooled olezarsen vs placebo, 0.12; 95% CI, 0.02 to 0.66).
  • Adverse events of moderate severity considered related to trial drug or placebo occurred in 4 patients (18%) in the 80-mg olezarsen group.

Methods

  • Phase 3, double-blind, placebo-controlled trial conducted from November 2020 through October 2023 at 29 centers in 11 countries; 66 patients with genetically identified familial chylomicronemia syndrome were randomized to olezarsen 80 mg (n=22), olezarsen 50 mg (n=21), or placebo (n=23) subcutaneously every 4 weeks for 49 weeks.
  • Patients had fasting triglycerides ≥880 mg/dL and biallelic loss-of-function variants in LPL or related genes; baseline mean triglyceride level was 2630±1315 mg/dL, and 71% had a history of acute pancreatitis within the previous 10 years.
  • Primary endpoints were hierarchical: difference between 80 mg and placebo in percent change in fasting triglycerides from baseline to 6 months, then the same for 50 mg vs placebo; secondary endpoints included apolipoprotein C-III change and independently adjudicated acute pancreatitis.

Limitations

  • The paper states the trial cohort was small and there was uncertainty about adherence to dietary restrictions, which could have affected triglyceride lowering and acute pancreatitis incidence.
  • The paper states the trial included mostly White patients, partly owing to genetic founder effects in European populations, and that larger, more diverse trials are needed.
  • The paper notes that because the second primary endpoint was not significant, secondary endpoint results cannot be interpreted as definitive hypothesis tests and their confidence intervals were not adjusted for multiplicity; it also states postprandial fluctuations were not measured.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2400201

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
From the PDF
Figure 1 Mean Percent Change from Baseline in Fasting Plasma Levels of Triglycerides and Apolipoprotein C-III Over Time.
Figure 1 Mean Percent Change from Baseline in Fasting Plasma Levels of Triglycerides and Apolipoprotein C-III Over Time.From the PDF
Figure 2 Kaplan-Meier Curves for the Time to the First Episode of Acute Pancreatitis.
Figure 2 Kaplan-Meier Curves for the Time to the First Episode of Acute Pancreatitis.From the PDF

Verification

Claims the paper makes

15 Valid · 3 Not valid · 7 Not checked · 64 Own results and interpretations

36 more claims · 4 with their cited sources checked

Create a free account to see all 89 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 26
  • It may state two separate claims as one. 33
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

31 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Cited by

See all 271

Metadata

Authors
Stroes, E. S. G., Alexander, V. J., Karwatowska-Prokopczuk, E., Hegele, R. A., Arca, M., Ballantyne, C. M., Soran, H., Prohaska, T. A., Xia, S., Ginsberg, H. N., Witztum, J. L., & Tsimikas, S.
Affiliations
  • Western University (CA)
  • From the Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, (E.S.G.S.); Ionis Pharmaceuticals, Carlsbad (V.J.A., E.K.-P., T.A.P., S.X., S.T.), and the Divisions of Endocrinology and Metabolism (J.L.W.) and Cardiovascular Medicine (S.T.), Department of Medicine, University of California, San Diego, La Jolla — both in California; the Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (R.A.H.); the Department of Translational and Precision Medicine, Center for Rare Disorders of Lipid Metabolism, Sapienza University of Rome, Rome (M.A.); Baylor College of Medicine and the Texas Heart Institute, Houston (C.M.B.); the National Institute for Health Research and Wellcome Trust Clinical Research Facility, Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom (H.S.); and the Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York (H.N.G.).
Venue
New England Journal of Medicine
Published
2024-05-16
Volume
390
Issue
19
Pages
1781-1792
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4394062061
Cited by
271
References
37
Citations by year
2026: 115 · 2025: 112 · 2024: 44
FWCI
81.10
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Funders
Ionis Pharmaceuticals
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
olezarsen, familial chylomicronemia syndrome, acute pancreatitis, hypertriglyceridemia, apolipoprotein C-III, antisense therapy, triglyceride lowering, hepatic triglyceride synthesis, dose comparison, drug safety and efficacy, adverse events, serious adverse events
MeSH terms
Acute Disease, Adult, Aged, Double-Blind Method, Female, Humans, Hyperlipoproteinemia Type I, Male, Middle Aged, Oligonucleotides, Pancreatitis, Triglycerides, Hypertriglyceridemia, Apolipoprotein C-III, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.